Zobrazeno 1 - 10
of 19
pro vyhledávání: ''
Autor:
Syed A. Hussain, Maria Vilarino-Varlela, Richard J. Jackson, Jeanette Lyons, Lisa Pickering, Jawaher Ansari, James D. Wylie, Robert Huddart, Derek G. Power, Nils O. Elander, Rhona McMenemin, Guy Faust, Seema Chauhan
Publikováno v:
International Journal of Oncology
There is no standard of care in the UK or Ireland for second-line chemotherapy for patients with advanced transitional cell carcinoma (TCCU). Vinflunine is approved for TCCU patients who have failed a platinum-based regimen, and is standard of care i
Autor:
Julia Dorn, Aurelia Noske, Tibor Schuster, Michaela Aubele, Rudolf Napieralski, Axel Walch, Magdalena Absmaier, Eva Gross, Marion Kiechle, Nadia Harbeck, Manfred Schmitt, Viktor Magdolen
Publikováno v:
International Journal of Oncology
Int. J. Oncol. 52, 755-767 (2018)
Int. J. Oncol. 52, 755-767 (2018)
Triple-negative breast cancer (TNBC) constitutes a heterogeneous breast cancer subgroup with poor prognosis; survival rates are likely to be lower with TNBC compared to other breast cancer subgroups. For this disease, systemic adjuvant chemotherapy r
Autor:
Georg Hopfinger, Stefan Stättner, Cornelia Hauser-Kronberger, Richard Greil, Hanno Ulmer, Franz Romeder, Gabriel Rinnerthaler, Florian Hohla, Angelika Bezan
Publikováno v:
International Journal of Oncology. 44:319-326
FOLFIRINOX is a highly active regimen for the treatment of patients with unresectable pancreatic cancer. However, treatment with FOLFIRINOX is associated with relevant toxicity and predictors for response to therapy are warranted. We retrospectively
Autor:
Azusa Sakamoto, Hiroki Nishikawa, Norihiro Nishijima, Akihiro Nasu, Toru Kimura, Shuhei Nishiguchi, Haruhiko Takeda, Yoshiaki Ohara, Ryuichi Kita, Yukio Osaki, Hideyuki Komekado, Sumio Saito
Publikováno v:
Oncology Reports. 31:65-72
The aim of the present study was to compare clinical outcomes in patients with intermediate-stage hepatocellular carcinoma (HCC) who underwent the following treatments: transcatheter arterial chemoembolization (TACE) using an epirubicin-mitomycin-lip
Autor:
Kohei Nakata, Kenoki Ohuchida, Tadashi Kayashima, Manabu Onimaru, Kazuhiro Mizumoto, Soichi Itaba, Tetsuhide Ito, Jun Yu, Tatsuro Tajiri, Tatsuya Manabe, Akifumi Hayashi, Masao Tanaka, Takao Ohtsuka, Hayato Fujita, Ryota Souzaki
Publikováno v:
International Journal of Oncology. 38
Pancreatic ductal adenocarcinoma (PDAC) still presents a major therapeutic challenge and a phase III clinical trial has revealed that the combination of gemcitabine and a human epidermal growth factor receptor type I (HER1/EGFR) targeting agent prese
Autor:
Shuji Takiguchi, Makoto Yamasaki, Hiroshi Miyata, Masaki Mori, Kiyokazu Nakajima, Yoshiyuki Fujiwara, Yuichiro Doki
Publikováno v:
Oncology Reports. 23
Patients with deeply invading (T3-T4) oesophageal cancers usually receive chemoradiotherapy with or without surgery. However, the prognostic significance of pre-therapy and post-therapy lymph node (LN) status remains unclear. We studied 195 patients
Autor:
Moo Suk Park, Joon Chang, Kyung Young Chung, Nae Choon Yoo, Chang Geol Lee, Se Kyu Kim, Joo Hang Kim, Byoung Chul Cho, Hye Jin Choi, Dae Joon Kim, Joohyuk Sohn, Beom Kyung Kim
Publikováno v:
Oncology Reports.
Thymic epithelial tumors (TETs) consist of a series of neoplasm that differ morphologically and biologically. Due to its rarity and indolent natural history, large-scale prospective trials have been lacking. This study aimed to evaluate long-term cli
Publikováno v:
Oncology Reports.
In this study, we have done a retrospective evaluation of the clinical benefits of neoadjuvant chemotherapy in 25 patients with stage IIIB, locally advanced breast cancer in terms of response rate and survival benefit. Most of these patients were tre
Autor:
Kunihiko Terada, Soichi Konno, Masashi Higashimoto, Takeshi Shimakawa, Shinobu Shirata, Shiro Mori, Kenji Ogawa, Yuji Takebayashi, Yoshihiko Naritaka, Toshihiro Sugiyama, Atsuko Kanzaki, Yasutaka Nitta, Ayumi Yoshida
Publikováno v:
International Journal of Molecular Medicine.
A major obstacle in the treatment of esophageal carcinoma is the intrinsic/acquired resistance to cisplatin-based chemotherapy. Copper-transporting P-type adenosine triphosphatase (ATP7B) has been reported to be associated with cisplatin resistance i
Autor:
Noe Kyeong Kim, Dae Ho Lee, Sung Whan Ha, Jooyoung Jung, Inho Kim, Keun Wook Lee, Dae-Young Kim, Hun Ho Song, Jae-Gahb Park, Tae-You Kim, Dae Seog Heo, Yung-Jue Bang
Publikováno v:
Oncology Reports.
This study was conducted to investigate the efficacy of the induction chemotherapy followed by radiotherapy in anal cancer. Twenty-three patients diagnosed with anal cancer between March 1991 and February 1999 were treated with induction chemotherapy